JP2017526698A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526698A5
JP2017526698A5 JP2017512759A JP2017512759A JP2017526698A5 JP 2017526698 A5 JP2017526698 A5 JP 2017526698A5 JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017526698 A5 JP2017526698 A5 JP 2017526698A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
pharmaceutically acceptable
composition
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512759A
Other languages
English (en)
Japanese (ja)
Other versions
JP6574245B2 (ja
JP2017526698A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048520 external-priority patent/WO2016037044A1/en
Publication of JP2017526698A publication Critical patent/JP2017526698A/ja
Publication of JP2017526698A5 publication Critical patent/JP2017526698A5/ja
Application granted granted Critical
Publication of JP6574245B2 publication Critical patent/JP6574245B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512759A 2014-09-05 2015-09-04 増殖性障害を処置するための組成物および方法 Expired - Fee Related JP6574245B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462046502P 2014-09-05 2014-09-05
US62/046,502 2014-09-05
US201462082236P 2014-11-20 2014-11-20
US62/082,236 2014-11-20
PCT/US2015/048520 WO2016037044A1 (en) 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149011A Division JP6837525B2 (ja) 2014-09-05 2019-08-15 増殖性障害を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017526698A JP2017526698A (ja) 2017-09-14
JP2017526698A5 true JP2017526698A5 (cg-RX-API-DMAC7.html) 2018-10-04
JP6574245B2 JP6574245B2 (ja) 2019-09-11

Family

ID=55436479

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512759A Expired - Fee Related JP6574245B2 (ja) 2014-09-05 2015-09-04 増殖性障害を処置するための組成物および方法
JP2019149011A Expired - Fee Related JP6837525B2 (ja) 2014-09-05 2019-08-15 増殖性障害を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019149011A Expired - Fee Related JP6837525B2 (ja) 2014-09-05 2019-08-15 増殖性障害を処置するための組成物および方法

Country Status (14)

Country Link
US (1) US9949981B2 (cg-RX-API-DMAC7.html)
EP (1) EP3189036B1 (cg-RX-API-DMAC7.html)
JP (2) JP6574245B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170045748A (cg-RX-API-DMAC7.html)
CN (2) CN107074769B (cg-RX-API-DMAC7.html)
AU (2) AU2015311751B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017004459A2 (cg-RX-API-DMAC7.html)
CA (1) CA2958770A1 (cg-RX-API-DMAC7.html)
ES (1) ES2955926T3 (cg-RX-API-DMAC7.html)
IL (2) IL250715B (cg-RX-API-DMAC7.html)
MX (1) MX382891B (cg-RX-API-DMAC7.html)
RU (2) RU2711500C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201701704XA (cg-RX-API-DMAC7.html)
WO (1) WO2016037044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3430405B1 (en) * 2016-03-14 2023-08-09 Pierce Biotechnology Inc. Detection and quantification of akt-mtor pathway proteins
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN110366413A (zh) * 2017-02-02 2019-10-22 Epizyme股份有限公司 癌症治疗形式
WO2019071171A1 (en) * 2017-10-05 2019-04-11 The Board Of Trustees Of The University Of Illinois Method of treating sickle cell disease
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
EP3880202A2 (en) * 2018-11-16 2021-09-22 ArQule, Inc. Pharmaceutical combination for treatment of cancer
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
US12617784B2 (en) 2019-01-29 2026-05-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
WO2020181009A1 (en) * 2019-03-04 2020-09-10 Northwestern University Bacterial enzymatic conversion of anthracyclie chemotherapeutics
WO2022053708A1 (en) * 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
AU2021351093A1 (en) * 2020-09-30 2023-06-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compound as akt kinase inhibitor
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof
KR20260065819A (ko) 2023-08-04 2026-05-11 테레모토 바이오사이언스, 인코포레이티드 AKT1의 비공유결합 변형제로서의 3H-이미다조[4,5-b]피리딘 화합물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036614A (en) * 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
US8049005B2 (en) * 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
CA2785536C (en) * 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
DK2723741T3 (en) 2011-06-24 2016-06-06 Arqule Inc SUBSTITUTED imidazopyridinyl-aminopyridine compounds

Similar Documents

Publication Publication Date Title
RU2017111204A (ru) Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний
JP2019501204A5 (cg-RX-API-DMAC7.html)
US20230235083A1 (en) Combination therapy using a liv1-adc and a chemotherapeutic
ES2744377T3 (es) Derivado de rapamicina para tratar cáncer de páncreas
JP2022533578A5 (cg-RX-API-DMAC7.html)
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
RU2018105655A (ru) Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
CN108135900A (zh) 包含瓦尼替尼及抗癌剂之组合疗法
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
JP2015517523A5 (cg-RX-API-DMAC7.html)
Inohara et al. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck
ES3019570T3 (en) Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a phy906 extract or a scutellaria baicalensis georgi (s) extract
Konopka‐Filippow et al. Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single‐institution experience
RU2014150860A (ru) Режим дозирования pi-3 киназы
JP2024512775A5 (cg-RX-API-DMAC7.html)
CN121311227A (zh) 用于治疗kras依赖性癌症的法尼基转移酶抑制剂
US20160128988A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
JP2021511344A5 (cg-RX-API-DMAC7.html)
US20060135527A1 (en) Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
JP2022515249A (ja) 癌の治療におけるドセタキセルの長期使用
JP2022514960A (ja) ドセタキセルおよびcyp3a阻害剤を用いる固形腫瘍の組み合わせ治療
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
Bahleda et al. Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors
RU2016116915A (ru) Комбинация
JP2023531090A5 (cg-RX-API-DMAC7.html)